When the Tumor’s Jazz Band Finds a New Bass Player

Cancer biology often sounds like an orchestra warming up - half the instruments are doing their own thing, someone is absolutely ignoring the conductor, and then one weird bass note turns out to be running the whole show. That bass note, in this new non-small cell lung cancer study, is a protein called SerpinB7 - a molecule most people were not exactly losing sleep over until it started acting like a backstage fixer for tumor metabolism.¹

The tumor’s snack addiction

Non-small cell lung cancer, or NSCLC, is the most common kind of lung cancer. One of its favorite tricks is something called glycolysis - basically, burning glucose fast and messily to support growth. Normal cells can do this too, of course, but cancer cells often crank it up to cartoonish levels. They behave like a city that keeps ordering takeout during a power outage instead of fixing the grid.

That metabolic rewiring is not just biochemical trivia. It helps tumors grow, spread, and survive in rough conditions. So when researchers find a new switch that controls glycolysis, people pay attention - or at least the sort of people who voluntarily read Molecular Cancer do.¹

In this paper, Zhao and colleagues found that SerpinB7 is overexpressed in NSCLC tissue and linked with worse prognosis.¹ That alone is interesting. But the more intriguing part is how it seems to help tumors.

SerpinB7: not doing the job on the label

SerpinB7 belongs to the serpin family, which usually makes you think of serine protease inhibition. Nice, tidy textbook category. Very reassuring. Naturally, this study says: actually, not that. SerpinB7 appears to promote cancer in a non-canonical, protease-independent way, which is science-speak for “the protein ignored its résumé and started freelancing.”¹

The key partner here is ANXA2 - Annexin A2 - a multitasking protein already implicated in cancer progression, invasion, and altered metabolism.[^2,^3] The authors report that SerpinB7 binds directly to ANXA2 and protects it from NEDD4L-mediated ubiquitination, which is one of the cell’s standard ways of tagging proteins for destruction.¹ In plainer English: SerpinB7 helps ANXA2 avoid getting thrown out.

That matters because ANXA2 then supports c-Myc, one of the most notorious cancer-promoting transcription factors in the business. And c-Myc, being c-Myc, pushes expression of genes involved in glycolysis.[^4,^5] So the proposed chain is:

SerpinB7 stabilizes ANXA2 -> ANXA2 supports c-Myc -> c-Myc boosts glycolysis -> tumor cells thrive.¹

It is a neat little relay team, if your hobbies include regretting how clever tumors can be.

Why c-Myc keeps showing up like the villain in a sequel

If you read enough cancer papers, c-Myc starts to feel like that one franchise antagonist who somehow survives every explosion. It regulates cell growth, metabolism, and proliferation, and when overactivated, it can push cells toward full chaos mode.[^4,^5] Reviews over the past few years keep pointing to Myc as a central driver of metabolic reprogramming, including enhanced glucose use and biomass production.[^4,^6]

That is what makes this SerpinB7-ANXA2-c-Myc axis worth noticing. The authors are not just saying “here is another overexpressed protein.” They are plugging SerpinB7 into one of cancer’s most famous control hubs. That gives the finding a bit more weight than random molecular gossip.

The part that could matter outside the lab

The study also tested a therapeutic angle: siRNA targeting SerpinB7, packaged inside ferritin protein nanocages, suppressed tumor growth and metastasis in experimental models.¹ That is the kind of result that makes everyone perk up and then immediately say, “okay, but let’s calm down.”

Because yes, it is promising. If SerpinB7 is relatively tumor-specific and helps sustain a pro-cancer metabolic state, then shutting it down could be useful. Metabolic targets in lung cancer remain attractive because tumors often lean hard on altered nutrient use, and disrupting that dependence might make them more vulnerable.[^6,^7]

But there are caveats. There are always caveats. I say this with the tender exhaustion of someone who has sat through many journal clubs.

This is still preclinical work. The delivery system, safety profile, durability of response, and relevance across different NSCLC subtypes all need much more testing.¹ Lung cancer is not one disease wearing one name tag. It is a whole messy family reunion. Also, metabolic pathways can be redundant, and tumors are annoyingly good at rerouting around blocked roads.

Why this paper sticks with you

What makes this study memorable is that it ties together three big cancer themes at once: protein stability, gene regulation, and metabolic rewiring.¹ It suggests SerpinB7 is not just hanging around as a marker of aggressive disease but may actively help build the biochemical conditions tumors prefer.

If the results hold up, SerpinB7 could become both a biomarker and a drug target in NSCLC. And if not, the work still teaches us something useful about how tumors keep their glycolytic engines humming. In cancer research, even the disappointing answers usually arrive wearing a fake mustache and pretending to be a new question.

That, scientifically speaking, is kind of the whole vibe.

References

Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.